RNA Aptamer Delivery through Intact Human Skin

Lenn, J.; Neil, Jessica; Donahue, Christine P.; Demock, Kellie; Tibbetts, Caitlin Vestal; Cote-Sierra, Javier; Smith, Susan; Rubenstein, David S.; Therrien, Jean-Philippe; Pendergrast, P. Shannon; Killough, Jason; Brown, Marc; Williams, Adrian C.

doi:10.1016/j.jid.2017.07.851

Cited by 32 publications

(13 citation statements)

References 21 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The improved half‐life of aptamers in vivo is suggestive of future clinical application as molecular imaging agents . Of note, aptamers themselves can be used as therapeutics in blood clotting, or local treatment, or inducing antitumor effect . Furthermore, aptamer‐mediated delivery systems have been broadly applied in cancer therapies, including aptamer‐drug conjugates, aptamer‐nanoparticle/polymer‐drug delivery system, and aptamer‐mediated cancer nucleic acid therapy .…”

Section: Aptamer Emerges As a Prominent Targeting Ligand For Nanodelimentioning

confidence: 99%

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

et al. 2019

View full text Add to dashboard Cite

Intense efforts from both scientists and physicians across Australia have been devoted onward advancing studies to fill the gap in understanding the biology and pathogenesis underlying cancer development. Exosomes are membrane-bound bio-nanoparticles secreted or released by most cells into the extracellular space. There has been an increasing interest in such bio-nanoparticles over the past 10 years, evident from the publication number of only 324 papers in 2006 to a massive increase to 4603 publications in 2018 with the search term "exosome" based on title/abstract in PubMed. Among these studies, 151 articles published from 2007 to 2018 are from Australian institutions, with 33 papers published in 2018. Such a strong surge of interest is due to discoveries that exosomes play key roles in intercellular and intertissue communication mediated by virtue of cargos contained inside the membrane-confined space. Furthermore, exosome cargos, including proteins, mRNAs and miRNAs, are linked to the Targeted exosomal delivery systems for precision nanomedicine attract wide interest across areas of molecular cell biology, pharmaceutical sciences, and nanoengineering. Exosomes are naturally derived 50-150 nm nanovesicles that play important roles in cell-to-cell and/or cell-to-tissue communications and cross-species communication. Exosomes are also a promising class of novel drug delivery vehicles owing to their ability to shield their payload from chemical and enzymatic degradations as well as to evade recognition by and subsequent removal by the immune system. Combined with a new class of affinity ligands known as aptamers or chemical antibodies, molecularly targeted exosomes are poised to become the next generation of smartly engineered nanovesicles for precision medicine. Here, recent advances in targeted exosomal delivery systems engineered by aptamer for future strategies to promote human health using this class of human-derived nanovesicles are summarized.The ORCID identification number(s) for the author(s) of this article can be found under https://doi.

show abstract

Section: Aptamer Emerges As a Prominent Targeting Ligand For Nanodelimentioning

confidence: 99%

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Theoretically, only small molecules with certain characteristics are able to penetrate tissues. However, it has been reported that even aptamers (~23.5 KDa) are able to penetrate tissues or even being translocated to the cells (Lenn et al 2018; Wang, Ding, and Zhou 2019). Our M1 aptamer could be further tested for cell permeability in appropriate laboratory facilities that could unlock novel approaches for in vivo visualization of TDF in the cell.…”

Section: Discussionmentioning

confidence: 99%

RNA beacons for detecting the human testis-determining factor

Nakamoto

Milón

2021

Preprint

View full text Add to dashboard Cite

The testis-determining factor (TDF) is an essential transcriptional protein for male differentiation in mammals, expressed along spermatids to early zygotes and, to some extent, in diverse cellular lines. In this study, we developed fluorescent biosensors capable of indicating the presence of TDF. We usedin vitroevolution techniques to produce RNA aptamers that bind the recombinantly expressed HMG-box, the DNA binding domain of TDF. Bioinformatic analysis alongin vitroevolution setup suggested two predominant aptamer clusters with distinctive motifs. The top ranked aptamer from each cluster, M1 and M2, showed specific binding to TDF. Aptamers were fluorescently modified as molecular beacons. Pre-steady-state kinetics indicated the beacons bind rapidly, within 50 seconds, yet M1 showed better signal to noise ratios than M2. Structural predictions of the aptamer interaction indicated that M1 is composed by three stem loops and likely interact with the HMG-box of TDF through the pocket formed by the three loops. Molecular modelling of M1 beacon shows that binding to TDF entails a conformational change of the sensor resulting in the measured fluorescence changes. To our knowledge, this is the first work describing an RNA beacon for detecting the essential TDF. Potential applications and advantages over alternative methods are provided and discussed.

show abstract

“…The use of topical siRNA is limited because of its low permeability through the epidermis, its high molecular weight, its negative charge, and its susceptibility to degradation by endogenous enzymes [62][63][64]. For this reason, efforts in topical siRNA delivery are being focused on chemical methods to prepared carrier molecules able to mask siRNA-negative charges, compress the siRNA molecule to make it smaller, and protect siRNA from degradation as well as the use of physical methods [65].…”

Section: Gene Therapy In Alopeciamentioning

confidence: 99%

Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia

Martínez-López

Montero‐Vílchez

Sierra-Sánchez

et al. 2020

IJMS

View full text Add to dashboard Cite

Alopecia is a challenging condition for both physicians and patients. Several topical, intralesional, oral, and surgical treatments have been developed in recent decades, but some of those therapies only provide partial improvement. Advanced medical therapies are medical products based on genes, cells, and/or tissue engineering products that have properties in regenerating, repairing, or replacing human tissue. In recent years, numerous applications have been described for advanced medical therapies. With this background, those therapies may have a role in the treatment of various types of alopecia such as alopecia areata and androgenic alopecia. The aim of this review is to provide dermatologists an overview of the different advanced medical therapies that have been applied in the treatment of alopecia, by reviewing clinical and basic research studies as well as ongoing clinical trials.

show abstract

RNA Aptamer Delivery through Intact Human Skin

Cited by 32 publications

References 21 publications

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

Exosomes and Nanoengineering: A Match Made for Precision Therapeutics

RNA beacons for detecting the human testis-determining factor

Advanced Medical Therapies in the Management of Non-Scarring Alopecia: Areata and Androgenic Alopecia

Contact Info

Product

Resources

About